BioCryst Pharmaceuticals
BCRX
BCRX
197 hedge funds and large institutions have $1.48B invested in BioCryst Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1.13% less ownership
Funds ownership: 58.87% → 57.74% (-1.1%)
10% less capital invested
Capital invested by funds: $1.65B → $1.48B (-$168M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
197
Holding in Top 10
2
Calls
$90.6M
Puts
$53.1M
Top Buyers
| 1 | +$17.4M | |
| 2 | +$14.3M | |
| 3 | +$12.3M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$10.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.99M |
Top Sellers
| 1 | -$37.4M | |
| 2 | -$11.2M | |
| 3 | -$9.89M | |
| 4 |
Renaissance Technologies
New York
|
-$8.97M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.82M |